Biotech Sage Therapeutics files for a $69 million IPO to fund treatments for deadly seizures

By
A A A

Sage Therapeutics, which is developing treatments for life-threatening seizures, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering. Each year, an estimated 30,000 patients die of status epilepticus, a condition where the brain is in a state of persistent seizure. Another biotech developing treatments for epilepsy, Marinus Pharmaceuticals ( MRNS ), filed for a $63 million IPO in May.

The Cambridge, MA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol SAGE. Sage Therapeutics initially filed confidentially on March 28, 2014. J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: MRNS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

100%

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com